Table 1.
Characteristics of patients in baseline analysis.
| Characteristics | Training set | P value | Test set | P value | ||
|---|---|---|---|---|---|---|
| Responders | Non-responders | Responders | Non-responders | |||
| Age, median (range) | 63 (35–84) | 64 (36–78) | 0.52 | 63 (29–75) | 62 (41–77) | 0.86 |
| Male | 64 (36–84) | 64 (36–78) | 63 (29–75) | 58 (41–74) | ||
| Female | 55 (43–79) | 61 (37–72) | 64 (43–72) | 74 (62–77) | ||
| Sex, No. (%) | ||||||
| Male | 68 (83.95%) | 44 (78.57%) | 0.42 | 31 (91.18%) | 22 (84.62%) | 0.71 |
| Female | 13 (16.05%) | 12 (21.43%) | 3 (8.82%) | 4 (15.38%) | ||
| Smoking history, No. (%) | ||||||
| Non-smokers | 22 (27.16%) | 17 (30.36%) | 0.68 | 8 (23.53%) | 8 (30.77%) | 0.53 |
| Smokers | 59 (72.84%) | 39 (69.64%) | 26 (76.47%) | 18 (69.23%) | ||
| Pathological type, No. (%) | ||||||
| Adenocarcinoma | 37 (45.68%) | 29 (51.79%) | 0.75 | 18 (52.94%) | 13 (50.0%) | 0.87 |
| Others | 44 (54.32%) | 27 (48.21%) | 16 (47.06%) | 13 (50.0%) | ||
| Distant metastasis, No. (%) | ||||||
| Absence | 21 (25.93%) | 5 (8.93%) | 0.01* | 8 (23.53%) | 2 (7.69%) | 0.20 |
| Presence | 60 (74.07%) | 51 (91.07%) | 26 (76.47%) | 24 (92.31%) | ||
| Treatment strategy, No. (%) | ||||||
| Monotherapy | 37 (45.68%) | 31 (55.36%) | 0.27 | 18 (52.94%) | 19 (73.08%) | 0.11 |
| Combination therapy | 44 (54.32%) | 25 (44.64%) | 16 (47.06%) | 7 (26.92%) | ||
| Rad-score (P25–P75) | ||||||
| Target lesions | −0.46 (−0.60, −0.30) | −0.41(−0.55, −0.21) | 0.27 | −0.42 (−0.57, −0.21) | −0.39 (−0.57, −0.22) | 0.54 |
| Largest target lesion | −0.20 (−0.21, −0.18) | −0.19 (−0.20, −0.17) | 0.10 | −0.20 (−0.21, −0.16) | −0.19 (−0.20, −0.17) | 0.89 |
*P value < 0.05.